Once‐weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study

Abstract

Aims: Real-world data are required to support glucagon-like peptide-1 receptor agonist use in type 2 diabetes (T2D). SURE France assessed once-weekly semaglutide in adults with T2D in real-world clinical practice. Materials andMethods: This multicentre, prospective, open-label, single-arm study included adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) value ≤12 weeks before semaglutide initiation. The primary endpoint was HbA1c change from baseline to end of study (EOS; $30 weeks). Secondary endpoints included change from baseline to EOS in body weight (BW) and waist circumference (WC); and proportion achieving HbA1c targets. Baseline characteristics and safety were reported for the full analysis set (patients initiating semaglutide). Analysis of other endpoints was based on the effectiveness analysis set (study completers receiving semaglutide at EOS).Results: Of 497 patients initiating semaglutide (41.6% female, mean age 58.3 years), 348 completed the study on treatment. Baseline HbA1c, diabetes duration, BW and WC, were 8.3%, 10.0 years, 98.2 kg and 114.2 cm, respectively. The most common reasons for initiating semaglutide were to improve glycaemic control (79.7%), reduce BW (69.8%) and address cardiovascular risk (24.1%). At EOS, mean changes were: HbA1c, -1.2% points [95% confidence interval (CI) -1.32; -1.10]; BW, -4.7 kg (95% CI -5.38; -4.07); and WC, -4.9 cm (95% CI -5.94; -3.88). At EOS, 81.7%, 67.7% and 51.6% of patients achieved an HbA1c target of <8.0%, <7.5% and <7.0%, respectively. No new safety concerns were identified.Conclusions: These results support the benefits of semaglutide in a real-world setting in adults with T2D in France showing a significant reduction in HbA1c and body weight.

Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study

“…This result is also superior to findings in real-world studies in cohorts followed in other settings; for example, 51.7% of the participants in the SURE France study achieved an HbA1c target of <7%. 10 In line with recent real-world studies, a decrease proportion of the semaglutide cohort concomitant glucose-lowering medications from baseline, in contrast, an increase proportion of non-GLP-1RA cohort in our study. 11 This implies that semaglutide may have been used to simplify the treatment regimen.…”

“…The overall percentage of participants achieving an HbA1c level <7% was slightly higher in our study than in the SUSTAIN 1–5 and 7 studies. This result is also superior to findings in real‐world studies in cohorts followed in other settings; for example, 51.7% of the participants in the SURE France study achieved an HbA1c target of <7% 10 …”

Weight Loss of Semaglutide Treatment for Patients With Overweight or Obesity: A Retrospective Observational Study in China

“…The program found that once-weekly administration of 1.0 mg or less of semaglutide resulted in a weight loss effect of 4.3 to 7.8 kg in patients with type 2 diabetes. [26][27][28][29][30][31][32][33][34] Retrospective studies above are similar to the results obtained in our study. In another retrospective study of 1.0 mg or less semaglutide after 2 years of follow-up, patients with diabetes had a weight loss of 9.72 kg.…”

Glycemic Control and Body Weight Reduction with Once-Weekly Semaglutide in Colombian Adults with Type 2 Diabetes: Findings from the COLIBRI Study

“…The glucose control outcomes in COLIBRI are similar to those of other real-world experiences. The SURE investigated OWS in a real-world setting in several European countries [ 9 – 16 ] and Canada [ 17 ]. The mean change in the SURE studies for HbA1c ranged from − 0.8% to − 1.5%.…”